Literature DB >> 23852084

Marine natural product des-O-methyllasiodiplodin effectively lowers the blood glucose level in db/db mice via ameliorating inflammation.

Rong Zhou1, Zhong-Hui Lin, Cheng-Shi Jiang, Jing-Xu Gong, Li-Li Chen, Yue-Wei Guo, Xu Shen.   

Abstract

AIM: des-O-methyllasiodiplodin (DML) from Cerbera manghas has shown antagonistic activity against mineralocorticoid receptor (MR). Considering the involvement of MR in the insulin tolerance, we attempted to investigate the potential of DML in the treatment of type 2 diabetes mellitus (T2DM).
METHODS: Surface plasmon resonance (SPR) technology and reporter gene-based assays were used to study protein-small molecule interactions. HepG2 and 3T3-L1 cells were treated with H2O2 (0.2 mmol/L) or aldosterone (10 nmol/L) for 24 h. The expression of MR in the cells was downregulated with siRNA. The anti-inflammatory effect of the compound was evaluated, respectively. db/db mice were administered DML (30 mg·kg(-1)·d(-1)) for 4 weeks. Serum biochemical parameters and insulin sensitivity were examined. The expression levels of pro-inflammatory cytokines (MCP-1, TNF-α and IL-6) and ROS-related genes (NADPH p47 subunit and transcriptional factor PU.1) in adipose tissues and livers were analyzed using real-time RT-PCR.
RESULTS: In HepG2 and 3T3-L1 cells, both H2O2 and aldosterone markedly stimulates the expression of MCP-1, TNFα, IL-6, p47 and PU.1 genes. Co-treatment with DML (10 μmol/L) significantly reduced the H2O2- or aldosterone-induced expression of these genes. SPR-based assay confirmed the antagonistic activity of DML against the interaction between SRC-1 and MR-LBD. Furthermore, DML decreased aldosterone-induced MR transcriptional activity in a dose-dependent manner. Downregulation of MR with siRNA in the cells prevented or significantly attenuated aldosterone-stimulated expression of these genes, whereas DML did no longer affect the expression of these genes except that of IL-6. Oral administration of DML effectively reduced the levels of blood glucose and glycosylated hemoglobin (HbA1c) in db/db mice. The treatment also rectified the expression of pro-inflammatory factor and ROS-related genes in db/db mice.
CONCLUSION: DML effectively lowers the blood glucose level in db/db mice possibly via ameliorating the expression of obesity-related pro-inflammatory cytokines, highlighting the potential of the marine natural product as a drug lead for the treatment of metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23852084      PMCID: PMC4002156          DOI: 10.1038/aps.2013.47

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  47 in total

Review 1.  Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation.

Authors:  Paresh Dandona; Ahmad Aljada; Ajay Chaudhuri; Priya Mohanty; Rajesh Garg
Journal:  Circulation       Date:  2005-03-22       Impact factor: 29.690

Review 2.  Mineralocorticoid receptors, salt, and hypertension.

Authors:  J W Funder; Z Krozowski; K Myles; A Sato; K E Sheppard; M Young
Journal:  Recent Prog Horm Res       Date:  1997

3.  Identification of a mineralocorticoid/glucocorticoid response element in the human Na/K ATPase alpha1 gene promoter.

Authors:  V Kolla; N M Robertson; G Litwack
Journal:  Biochem Biophys Res Commun       Date:  1999-12-09       Impact factor: 3.575

4.  Insulin signalling and the regulation of glucose and lipid metabolism.

Authors:  A R Saltiel; C R Kahn
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

5.  PU.1 is essential for p47(phox) promoter activity in myeloid cells.

Authors:  S L Li; A J Valente; S J Zhao; R A Clark
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

6.  Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel.

Authors:  P M Snyder; M P Price; F J McDonald; C M Adams; K A Volk; B G Zeiher; J B Stokes; M J Welsh
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

7.  Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.

Authors:  Weijia Kong; Jing Wei; Parveen Abidi; Meihong Lin; Satoru Inaba; Cong Li; Yanling Wang; Zizheng Wang; Shuyi Si; Huaining Pan; Shukui Wang; Jingdan Wu; Yue Wang; Zhuorong Li; Jingwen Liu; Jian-Dong Jiang
Journal:  Nat Med       Date:  2004-11-07       Impact factor: 53.440

8.  PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension.

Authors:  P Ferrari; M Ferrandi; G Tripodi; L Torielli; G Padoani; E Minotti; P Melloni; G Bianchi
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

9.  Toxicity and effects on the central nervous system of a Cerbera odollam leaf extract.

Authors:  T T Hiên; C Navarro-Delmasure; T Vy
Journal:  J Ethnopharmacol       Date:  1991-09       Impact factor: 4.360

10.  Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism?

Authors:  K Shimamoto; M Shiiki; T Ise; Y Miyazaki; K Higashiura; M Fukuoka; A Hirata; A Masuda; M Nakagawa; O Iimura
Journal:  J Hum Hypertens       Date:  1994-10       Impact factor: 3.012

View more
  1 in total

1.  Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A.

Authors:  Yi Zheng; Xia Li; Piyusha P Pagare; Yunyun Yuan; Xiang-Yang Wang; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2016-11-12       Impact factor: 2.823

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.